McKesson Eyes Option Care Deal With CD&R

McKesson is reportedly considering an acquisition of Option Care, a move that could be announced soon. Option Care's stock rose 21% on the news, reflecting market expectations of a $5 billion deal. McKesson declined to comment on the potential acquisition.

Original reporting
Published Oct 5, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
McKesson Eyes Option Care Deal With CD&R — source image
Decision brief

The 30-second read

$MCKBullishMed
01

Why it matters

If the deal proceeds, McKesson could expand its specialty pharmacy footprint, while Option Care shareholders may receive a premium.

02

Market read

The rumored $5 billion deal could reshape the healthcare distribution landscape and move both stocks.

03

What to watch

Regulatory approval risk and financing terms could delay or derail the transaction.

Relevance 8/10Novelty 8/10Timing: potential announcement as early as Tuesday

Background

McKesson, a leading drug distributor, is exploring a takeover of Option Care Health, a specialty pharmacy provider, with private‑equity firm CD&R involved.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson is reported to be negotiating a potential $5 billion acquisition of Option Care Health.

Expected impact

likely upside as market prices in acquisition premium expectations

Evidence & confidence

First report of a large‑scale M&A talks; $5 B size is material for both mid‑cap participants.

$OPCHBullishHigh confidence
Context

Option Care Health is the target of a rumored $5 billion acquisition by McKesson.

Expected impact

likely upside driven by acquisition premium expectations

Evidence & confidence

Deal rumors are fresh and sizable, creating immediate pricing pressure on the target.

Market effects

Consolidation trend in healthcare distribution could pressure peers.

U.S. healthcare sector may see modest rally on M&A optimism.

Large deal size underscores ongoing consolidation in global pharma supply chains.

Counterpoint

Deal could fall apart, causing a sell‑off in both stocks if negotiations stall.

Key entities

  • McKesson Corporation

    U.S. drug distributor and potential acquirer.

  • Option Care Health

    Specialty pharmacy services provider and acquisition target.

  • Clayton, Dubilier & Rice

    Financial sponsor involved in the potential transaction.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.